CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Association of Cardiovascular Disease With Respiratory Disease Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Dapagliflozin for treating chronic heart failure with reduced ejection fraction AIM2-driven inflammasome activation in heart failure The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure
|<<... 10 11 12 13 14 15 16 >>|

Review ArticleVolume 72, Issue 19, November 2018

JOURNAL：J Am Coll Cardiol. Article Link

Ejection Fraction Pros and Cons: JACC State-of-the-Art Review

TH Marwick Keywords: ejection fraction; heart failure; myocardial infarction; strain; valvular heart disease

ABSTRACT

Ejection fraction (EF) reflects both cardiac function and remodeling, and is widely recognized as a valuable diagnostic and prognostic tool. Its use in a variety of settings, ranging from heart failure and myocardial infarction to valvular heart disease, has made it a cornerstone of modern cardiology, pervading guidelines and practice. However, the development of the test was in another era, with younger patients and a lower prevalence of heart failure with preserved EF. The performance expectations of EF in the current era are also demanding-in relation to detection of subclinical LV dysfunction, and especially relating to recognition of changes in LV function on sequential testing-for example in patients taking cardiotoxic drugs. This review discusses whether the impressive evidence base for EF justifies its ongoing use in the context of newer markers of LV function, and the sophisticated questions posed by modern cardiology.



>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top